NCT03729180

The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery

Recruiting now NA Last updated 29 December 2025

What this trial tests

NA trial testing Routine Elective Surgery- In patient or out patient elective surgery in Surgery in 1,900 participants. Currently enrolling.

Timeline

22 January 2019

Primary endpoint
22 August 2027

22 August 2027

Quick facts

Lead sponsor	University of Chicago
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	supportive care
Enrollment	1,900
Start date	22 January 2019
Primary completion	22 August 2027
Estimated completion	22 August 2027
Sites	1 location across United States

Drugs / interventions tested

• Routine Elective Surgery- In patient or out patient elective surgery
• Blood test for genetic testing
• Drug-genetic Profile

Conditions studied

• Surgery — all drugs for Surgery →

Sponsor

University of Chicago

Who can join

18 and older, any sex, with Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago.

At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.

Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS).

Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients.

There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase

After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care.
   Truong TM, Apfelbaum J, Shahul S, Anitescu M, et al · · 2019 · cited 16× · PMID 31433489 · DOI 10.1002/cpt.1567
2. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial.
   Truong TM, Apfelbaum JL, Danahey K, Schierer E, et al · · 2022 · cited 7× · PMID 35213469 · DOI 10.1213/ane.0000000000005951
3. Pharmacogenomic considerations for medications in the perioperative setting.
   Jhun EH, Apfelbaum JL, Dickerson DM, Shahul S, et al · · 2019 · cited 5× · PMID 31411557 · DOI 10.2217/pgs-2019-0040
4. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.
   Truong TM, Apfelbaum JL, Schierer E, Danahey K, et al · · 2022 · cited 1× · PMID 34570085 · DOI 10.1097/fpc.0000000000000455